A Pilot Study to Evaluate the Efficacy of IZN 6D4 for the Treatment of Diabetic Foot Ulcers – “Journal of Diabetic Complications & Medicine”

The attached publication in the “Journal of Diabetic Complications & Medicine” by the authors Jonathan Rosenblum and Menachem Oberbaum describes the first ever experience with Curasite® in man.  This pilot study led to the larger double-blind effort that resulted in FDA clearance of the product.

The pilot study showed strong evidence of a wound healing effect by Curasite to treat resistant diabetic foot ulcers (DFUs) with many patients achieving complete wound closure, results that were replicated in the larger blinded multi-center study.

The FDA has cleared Curasite for the following prescription uses:

  • Diabetic foot ulcers
  • Leg ulcers, including venous stasis ulcers, arterial ulcers, and ulcers of mixed etiology
  • Full and partial thickness pressure ulcers
  • 1st and 2nd-degree partial thickness burns.

Curasite is also approved for the following over the counter (OTC) uses:

  • Minor abrasions
  • Minor lacerations
  • Minor cuts
  • Minor scalds and burns.

The FDA claims are extensive and, importantly, position Curasite as first-line therapy for these patients. Due to the unprecedented efficacy of Curasite, Izun intends to pursue other indications for this remarkable wound healing product.